[ad_1]
The Covishield was supposed to launch nationwide on Friday after vaccinating the country’s prime minister and several cabinet members, but was later scrapped.
Several countries, including Denmark and Norway, have suspended the use of the AstraZeneca vaccine, prompting Thailand to make a late decision on the vaccine, the BBC reported.
Approximately 5 million people in Europe have already received the Covishield vaccine from Oxford-AstraZeneca; Thirty-six people have been found to have side effects from blood clots.
However, the European Medicines Agency (EMA) said Thursday that it had found no evidence of blood clots in the estrogen vaccine.
They also commented that the benefits of the AstraZeneca vaccine “outweigh the risk.”
Officials at Thailand’s Ministry of Public Health say the batch of AstraZeneca tickers that have been distributed in Europe is no longer the same.
They also said that no side effects of blood clotting have been identified among vaccinators in Asia.
“Despite the good quality of the astragenera (ticker) vaccines, some countries want to delay the introduction of the vaccine. We will also be late,” Piasakal Sakalsatayadorn, advisor to the Kovid-19 vaccine committee in Thailand, told reporters.
The country received one lakh 17,300 doses of the AstraZeneca vaccine on February 24; At the same time, 200,000 doses of the Chinese Coronavac vaccine arrived in the country.
Coronavac has been used in Thailand since February 26; The BBC reports that some 30,000 people have already been vaccinated.
Coronavac will continue to be administered despite the late decision to administer the AstraZeneca vaccine, Thailand said.
[ad_2]
